Technology | July 08, 2015

Masimo Receives CE Mark for MightySat Rx Pulse Oximeter

Wireless fingertip pulse oximeter enables clinicians to track and trend measurements through smart mobile devices

Masimo, MightySat Rx, fingertip pulse oximeter, SpO2, pulse rate

July 8, 2015 - Masimo announced the CE Mark and full market release of MightySat Rx fingertip pulse oximeter for clinical use in CE countries. The device uses Masimo's SET Measure-Through Motion and Low Perfusion pulse oximetry.

Bluetooth-enabled versions of MightySat Rx allow clinicians to track and trend up to 12 hours of patient measurements on smart mobile devices, and to share that data via standard CSV files as well as transfer to Apple's Health app.

MightySat Rx enables accurate noninvasive spot-checking of oxygen saturation (SpO2) and pulse rate (PR) for adult and pediatric patients even during motion and low perfusion. The device measures and displays perfusion index (PI), which reflects the strength of the pulsatile signal. MightySat can also measure and display Pleth Variability Index (PVI), a measure of the dynamic changes in the perfusion index that occur during one or more complete respiratory cycle/s.

MightySat Rx is available in three versions for patients who weigh more than 30 kg (66 lbs):

  • MightySat Rx – Measures and displays SpO2, PR, and PI;
  • MightySat Rx, Bluetooth – Adds Bluetooth LE radio for transfer of parameter data to Apple iOS and select Android mobile devices;
  • MightySat Rx, Bluetooth and PVI.

 

Standard features include:

  • Measure-Through Motion and Low Perfusion performance;
  • Signal I.Q. to assess measurement confidence;
  • Rugged, lightweight design for operation in challenging environments;
  • Long battery life – up to 15 hours with two standard AAA alkaline batteries; and
  • Comfortable design with silicon finger pad to mold to patients' fingers.

 

For more information: www.masimo.com


Related Content

News | Cardiac Diagnostics

Aug. 13, 2024 – The traditional lipid panel may not give the full picture of cholesterol-related heart disease risk for ...

Home August 15, 2024
Home
Feature | Cardiac Diagnostics | By Robert L. Quigley, MD, DPhil

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes ...

Home January 23, 2024
Home
News | Cardiac Diagnostics

September 5, 2023 — GE HealthCare announced the launch of a handheld, wireless ultrasound imaging system designed for ...

Home September 05, 2023
Home
Feature | Cardiac Diagnostics | By Kelly Patrick

The global ambulatory diagnostic cardiology market was valued at $2.6 billion in 2022 and is forecast to rise to $3.3 ...

Home May 15, 2023
Home
News | Cardiac Diagnostics

February 8, 2023 — Results of research that identified new causes of Atherosclerotic Coronary Artery Disease, or ASCAD ...

Home February 08, 2023
Home
News | Cardiac Diagnostics

September 15, 2022 - Happitech has announced the launch of its FastStart Research app. The Amsterdam-based digital ...

Home September 15, 2022
Home
Feature | Cardiac Diagnostics | by Kelly Patrick

Like most healthcare markets, the diagnostic cardiology market has had a bumpy ride in recent years. The COVID-19 ...

Home August 23, 2022
Home
Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Subscribe Now